Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

1 passage

abstractpubmed· Abstract 2021· item PMID:34871049

Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin. SOURCE CITATION: Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609-17. 34297496.